[The Roles of Aβ in Alzheimer's Disease: In Light of the Latest Findings]
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.The amyloid hypothesis suggests amyloid beta (Aβ) causes Alzheimer's disease. Emerging evidence points to toxic Aβ oligomers, not plaques, driving neurodegeneration, guiding new therapeutic strategies.
Area Of Science
- Neuroscience
- Biochemistry
Context
- The traditional amyloid hypothesis links Alzheimer's disease (AD) neurodegeneration to amyloid-beta (Aβ) plaques.
- However, recent research challenges this, focusing on the neurotoxic potential of soluble Aβ aggregates.
Purpose
- To explore the shift in understanding AD pathogenesis from mature amyloid plaques to intermediate Aβ aggregates.
- To highlight the therapeutic implications of targeting toxic Aβ oligomers.
Summary
- The amyloid hypothesis posits that amyloid-beta (Aβ) aggregation leads to neurodegeneration in Alzheimer's disease (AD).
- Initially, mature fibrils and plaques were considered the primary neurotoxic agents.
- The 'Aβ oligomer hypothesis' now emphasizes the heightened neurotoxicity of intermediate aggregates like oligomers and protofibrils.
Impact
- This evolving understanding is driving the development of novel therapeutic strategies for AD.
- Targeting specific Aβ oligomeric species offers a promising avenue for disease-modifying treatments.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...